Temporomandibular dysfunctions are myoarthropathies of the manducatory apparatus, responsible in most cases of chronic pain without satisfactory treatment. Lately, methods of administering active ingredients via hydrogels have attracted a lot of attention. UMET and U1008 laboratories have developed a patented hydrogel based on chitosan (CHT) and cyclodextrin polymer (PCD) for the release of active ingredients. The objective of this project is to evaluate and optimize the hydrogel to meet the specifications: viscoelastic properties; release of nonsteroidal anti-inflammatory drugs (NSAIDs) over 3 weeks; therapeutic efficacy in vivo. The base of the hydrogel will be maintained by adding hyaluronic acid. A rheological screening will be carried out to find the ideal formation. Naproxen release studies and in vivo studies with winstar rats will be performed.
Madame Maria-Jose GARCIA FERNANDEZ (U 1008 - ADDS - Systèmes avancés de délivrance de principes actifs - Advanced Drug Delivery Systems)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
U1008 U 1008 - ADDS - Systèmes avancés de délivrance de principes actifs - Advanced Drug Delivery Systems
Help of the ANR 267,423 euros
Beginning and duration of the scientific project:
September 2021
- 42 Months
